Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy

dc.authorid0000-0002-8047-5553
dc.authorid0000-0002-8851-6559
dc.authorid0000-0001-9829-7268
dc.authorid0000-0001-5335-3860
dc.authorid0000-0001-7399-5764
dc.contributor.authorAras, Cengiz
dc.contributor.authorŞentürk, Fevzi
dc.contributor.authorKaraman Erdur, Sevil
dc.contributor.authorKocabora, Mehmet Selim
dc.contributor.authorDoğramacı, Mahmut
dc.contributor.authorBurke, Cahit
dc.contributor.authorAras, Efe
dc.date.accessioned2024-03-22T07:02:25Z
dc.date.available2024-03-22T07:02:25Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPURPOSE: To investigate the clinical benefits of the co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy. METHODS: Patients who underwent vitrectomy for proliferative diabetic retinopathy complications were preoperatively given intravitreal injection with either bevacizumab and tissue plasminogen activator (Group 1) or bevacizumab alone (Group 2). Primary outcomes were surgery time and number of intraoperative iatrogenic retinal breaks. Secondary outcomes included changes in the best-corrected visual acuity and postoperative complications at 3 months postoperatively. RESULTS: The mean surgery time in Group 1 (52.95 +/- 5.90 min) was significantly shorter than that in Group 2 (79.61 +/- 12.63 min) (p<0.001). The mean number of iatrogenic retinal breaks was 0.50 +/- 0.59 (0-2) in Group 1 and 2.00 +/- 0.83 (0-3) in Group 2 (p<0.001). The best-corrected visual acuity significantly improved in both groups (p<0.001). One eye in each group developed retinal detachment. CONCLUSION: Preoperative co-application of bevacizumab and tissue plasminogen activator as adjuncts in the surgical treatment of proliferative diabetic retinopathy shortens the surgery time and reduces the number of intraoperative iatrogenic retinal breaks.
dc.identifier.citationAras, C., Şentürk, F., Karaman Erdur, S., Kocabora, M. S., Doğramacı, M., Burke, C. ... Aras, E. (2024). Preoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy. Arquivos Brasileiros de Oftalmologia, 87(2). https://dx.doi.org/10.5935/0004-2749.2023-0001
dc.identifier.doi10.5935/0004-2749.2023-0001
dc.identifier.issn0004-2749
dc.identifier.issn1678-2925
dc.identifier.issue2
dc.identifier.pmid38451688
dc.identifier.scopus2-s2.0-85187207105
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://dx.doi.org/10.5935/0004-2749.2023-0001
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12389
dc.identifier.volume87
dc.identifier.wos001182427100001en_US
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAras, Cengiz
dc.institutionauthorŞentürk, Fevzi
dc.institutionauthorKaraman Erdur, Sevil
dc.institutionauthorKocabora, Mehmet Selim
dc.institutionauthorBurke, Cahit
dc.language.isoen
dc.publisherConsel Brasil Oftalmologia
dc.relation.ispartofArquivos Brasileiros de Oftalmologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiabetic Retinopathy
dc.subjectBevacizumab
dc.subjectPlasminogen Activators
dc.subjectVitrectomy
dc.subjectOperative Time
dc.titlePreoperative co-application of bevacizumab and tissue plasminogen activator in vitrectomy for proliferative diabetic retinopathy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Aras-Cengiz-2024.pdf
Boyut:
161.27 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: